CBER outlines future biologics, biosimilars plans

With greater development of biologic medications, biosimilars and companion diagnostics, the FDA Center for Biologics Evaluation and Research's role in health care is growing, speakers said at FDLI's annual meeting. CBER office directors discussed plans for the center, which include a push to publish the draft guidance Preclinical Safety Assessment of Investigational Cellular and Gene Therapy Products.

View Full Article in:

CBER Importance Boosted With Attention To Biologic Drugs, Biosimilars, Speakers Say - Bloomberg BNA

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC